|
|
| (17 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT[[Miconazole (topical)]] |
| |authorTag={{KS}}
| |
| |genericName=Miconazole nitrate
| |
| |aOrAn=an
| |
| |drugClass=antifungal agent, anti-infective agent
| |
| |indicationType=treatment
| |
| |indication=[[candidal vulvovaginitis, tinea]], [[superficial]]
| |
| |adverseReactions=[[Contact dermatitis]]
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| |
| | |
| * Content
| |
| | |
| <!--Adult Indications and Dosage-->
| |
| | |
| <!--FDA-Labeled Indications and Dosage (Adult)-->
| |
| |fdaLIADAdult===Indications==
| |
| * For treatment of most athlete's foot (tinea pedis), jock itch (tinea crusis), Ringworm (tinea corporis).
| |
| | |
| * For the treatment of superficial skin infections caused by Yeast ([[Candida Albicans]]).
| |
| | |
| * Relieves [[itching]], scaling, cracking, burning, redness, soreness, irritation discomfort and chafing associated with jock itch.
| |
| | |
| * Candidal vulvovaginitis
| |
| | |
| ==Dosing==
| |
| | |
| * Candidal vulvovaginitis: (suppository) 200 mg INTRAVAGINALLY at bedtime for 3 days OR 100 mg INTRAVAGINALLY at bedtime for 7 days OR 1200 mg INTRAVAGINALLY once.
| |
|
| |
| * Candidal vulvovaginitis: (cream) insert 1 applicatorful (5 g) of 2% cream INTRAVAGINALLY daily for 7 days, or 1 applicatorful (5 g) of 4% cream INTRAVAGINALLY daily for 3 days.
| |
| | |
| * Candidal vulvovaginitis: (HIV patients, duration) uncomplicated cases, 3 to 7 days; severe or recurrent, 7 or more days.
| |
| | |
| * Tinea, Superficial: apply TOPICALLY to affected areas twice daily.
| |
| | |
| |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| |fdaLIADPed===Indication==
| |
| * Candidal vulvovaginitis.
| |
| * Tinea, Superficial
| |
| | |
| ==Dosage==
| |
| * Candidal vulvovaginitis: 12 yr and older, 200 mg VAGINALLY at bedtime for 3 days.
| |
| * Candidal vulvovaginitis: 12 yr and older, 100 mg VAGINALLY at bedtime for 7 days.
| |
| * Candidal vulvovaginitis: 12 yr and older, 1200 mg VAGINALLY once.
| |
| * Tinea, Superficial: (2 yr and older) apply TOPICALLY to affected areas twice daily
| |
| |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| |offLabelPedNoGuideSupport===Indication==
| |
| * Diaper rash<ref name="pmid11358560">{{cite journal| author=Concannon P, Gisoldi E, Phillips S, Grossman R| title=Diaper dermatitis: a therapeutic dilemma. Results of a double-blind placebo controlled trial of miconazole nitrate 0.25%. | journal=Pediatr Dermatol | year= 2001 | volume= 18 | issue= 2 | pages= 149-55 | pmid=11358560 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11358560 }} </ref>
| |
| |warnings='''Do not use''':
| |
| | |
| * Do not use on children under 2 years of age unless directed by a doctor.
| |
| | |
| * Avoid contact with eyes.
| |
| | |
| * For athletes foot and ringworm - if irritation occurs, or if there is no improvement within 4 weeks, discontinue use and consult a doctor.
| |
| | |
| * For jock itch - if irritation occurs, or if there is no improvement within two weeks, discontinue use and consult a doctor.
| |
| | |
| * Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
| |
| |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
| |
| |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
| |
| |useInPregnancyFDA=*
| |
| |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
| |
| | |
| There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
| |
| |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
| |
| |useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
| |
| |useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
| |
| |useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
| |
| |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
| |
| |useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
| |
| |useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
| |
| |useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
| |
| |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
| |
| |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
| |
| | |
| | |
| |administration=* Oral
| |
| | |
| * Intravenous
| |
| |monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| | |
| <!--IV Compatibility-->
| |
| |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| |overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| | |
| <!--Drug box 2-->
| |
| |mechAction=
| |
| | |
| | |
| |structure=
| |
| | |
| | |
| |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| |howSupplied=*
| |
| |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| | |
| | |
| |drugShortage=
| |
| }}
| |
| {{PillImage
| |
| |fileName=No image.jpg
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| <!--Pill Image-->
| |
| | |
| | |
| | |
| <!--Label Display Image-->
| |
| | |
| | |
| | |
| | |
| | |
| <!--Category-->
| |
| | |
| [[Category:Drug]]
| |